Raltegravir + Abacavir-Lamivudine

SHIELD Trial
Raltegravir + Abacavir-Lamivudine
SHIELD: Study Design

Study Design: SHIELD

- **Background**: Open-label, prospective, pilot trial evaluating efficacy of raltegravir in combination with abacavir-lamivudine in treatment-naïve persons with HIV.

- **Inclusion Criteria** (n = 37)
  - Age ≥18 years
  - Antiretroviral therapy naïve
  - HIV RNA >1000 copies/mL
  - HLA-B*5701 negative
  - No resistance to any study drug

- **Treatment Arm**
  - Raltegravir 400 mg BID + Abacavir-Lamivudine QD

Raltegravir + Abacavir-Lamivudine
SHIELD: Result

Week 48: Virologic Response (missing/discontinuation = failure)

![Graph showing virologic response](image)

- **Overall**: 32/35 (91%)
- **<100,000 copies/mL**: 20/23 (87%)
- **≥100,000 copies/mL**: 12/12 (100%)

Raltegravir + Abacavir-Lamivudine
SHIELD: Result

Week 48: Changes in Lipid Concentrations

Conclusions: “In this pilot study, abacavir/lamivudine plus raltegravir was effective and generally well-tolerated over 48 weeks with modest changes in fasting lipids.”
The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.

*The content in this presentation are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.*